Refine by
Innate Immunity Articles & Analysis
46 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
With a strong focus on unpicking the glycobiology of the innate immune system, the group seeks to advance molecular and cellular understanding of the role of glycoproteins in immune-related disorders including in cancer and inflammation and upon pathogen infections including sepsis, tuberculosis and cystic fibrosis. ...
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted in a statistically ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
Highlights: ES004 recognizes pan-allele human SIRPα with high affinity ES004 binds to a unique epitope on the CD47 binding domain of SIRPα ES004 potently blocks CD47-SIRPα interaction and CD47 induced SIRPα signaling ES004 effectively potentiates pan-allelic macrophage phagocytosis of tumor cells ES004 has no negative impact on T cell activation ES004 enhances ...
.: 793 Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST) 4. Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity Abstract No.: 1211 Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST) 5. ...
Presentation Details Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Abstract Number: 751 Presentation Type: Poster Presentation Onsite Location: Poster Hall Date: November 10, 2022 9 a.m. ...
The trial sponsor is INmune Bio, a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that harness the patient’s innate immune system to fight disease. The trial will use CDM® technology to assess the efficacy of XPro™ compared with placebo on grey matter integrity in patients with mild AD. ...
Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant ...
Gamma-delta T cells are the prototype of ‘unconventional’ T cells, having both innate and adaptive immune properties. These unique properties hold promise in treating solid tumors, the ‘Achilles heel’ of adoptive cell therapies. ...
“This advisory board brings together invaluable expertise in hematological and solid cancers as well as the biology of NK cells and their application to further the development of our novel and highly potent innate immune cell-engaging therapies.” Dr. Fehniger of Washington University School of Medicine added, “This is an exciting time for ...
We believe our differentiated approach in targeting CD123 has the potential to provide a novel, innate immune system-engaging therapy to improve clinical outcomes,” said Dr. ...
Presented a poster at NK2022 conference featuring an analysis of the longitudinal effects of AFM24 in patients treated in AFM24-101, confirming the mechanism of action of AFM24 on the innate immune system. Preclinical Programs AFM28 (CD123/CD16A) AFM28 is a bispecific, tetravalent ICE® that targets CD16A on NK cells and macrophages, and CD123 on ...
AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 22, 2022 at 09:00 a.m. ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022. ...